Skip to content
StackItSmart
BHuman cohort / observational

Gonadorelin

GnRH

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), the natural decapeptide the hypothalamus releases in pulses to drive the pituitary to secrete LH and FSH. In legitimate medicine it is used mainly as a diagnostic agent (an IV LH/FSH-reserve stimulation test) and, far less commonly, as a chronic pulsatile infusion via a programmable pump to induce puberty, testicular growth, and sperm production in men with hypothalamic (secondary) hypogonadism. Its defining feature and its central danger for self-use is that its action depends entirely on being delivered in correctly-timed low-dose pulses: native GnRH has a half-life of only minutes, so steady or high-dose exposure paradoxically downregulates pituitary receptors and suppresses gonadotropins rather than raising them. It is not a substitute for hCG and there is no human evidence supporting the common community claim that intermittent subcutaneous gonadorelin maintains testicular function or restarts the axis during or after anabolic steroid use. The main dangers are acute anaphylaxis (documented, including a life-threatening pediatric case), the need for physiologic pulsatile dosing that is impractical outside a clinic, and false reassurance leading people to neglect real endocrine evaluation. Anyone using or considering it should be under an endocrinologist and should not self-manage HPTA recovery.

Clinical readoutPeptide · hpg-axis
Hepatic strainLow
CardiovascularNone
HPTA suppressionHigh
Half-life
7 min
Route
Intravenous bolus for d…
Evidence
B
Active
Minutes
7 min14 min20 min27 min34 min
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Very short. Exogenous GnRH cleared with an initial plasma half-disappearance time of roughly 5.5-8 minutes in healthy subjects (essentially unchanged with moderate liver disease); prolonged to about 12-16.5 minutes in chronic renal failure (Pimstone 1977, PMID 320223).
Pharmacology

Mechanism of action

Gonadorelin is identical to endogenous GnRH (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2). It binds GnRH receptors on anterior pituitary gonadotroph cells, activating Gq/phospholipase-C signaling and triggering synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive testicular Leydig-cell testosterone production and Sertoli-cell/germ-cell spermatogenesis (or ovarian steroidogenesis and folliculogenesis). The pharmacodynamic response is critically dependent on the pattern of exposure: intermittent, physiologically-timed pulses (roughly every 60-120 min) sustain gonadotropin secretion, whereas continuous or high-amplitude non-pulsatile exposure causes receptor downregulation and desensitization, suppressing LH/FSH — the same principle by which long-acting GnRH agonists achieve chemical castration.
Kinetics

Pharmacokinetics

Half-life

Very short. Exogenous GnRH cleared with an initial plasma half-disappearance time of roughly 5.5-8 minutes in healthy subjects (essentially unchanged with moderate liver disease); prolonged to about 12-16.5 minutes in chronic renal failure (Pimstone 1977, PMID 320223).

Active duration

Minutes. A single dose produces a transient LH/FSH pulse lasting on the order of 1-2 hours; there is no sustained drug depot, which is why therapeutic use requires repeated pulsatile dosing via pump.

Route

Intravenous bolus for diagnostic LH/FSH stimulation testing; subcutaneous or intravenous pulsatile infusion via a programmable pump for therapeutic induction of spermatogenesis/puberty. No oral bioavailability (peptide).

Metabolism & clearance

Rapid enzymatic degradation by peptidases in plasma and tissues; the kidney appears to be an important catabolic/clearance organ. Metabolic clearance rate ~1640 mL/min in healthy adults, roughly halved (~631 mL/min) in chronic renal failure; moderate hepatic dysfunction did not significantly alter clearance (Pimstone 1977, PMID 320223).

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Transiently raises serum LH and FSH after a pulse or bolus (basis of the diagnostic GnRH stimulation test of pituitary gonadotropin reserve)
  • When given as long-term pulsatile infusion in men with hypogonadotropic hypogonadism (idiopathic, Kallmann syndrome, post-surgical): increases testicular volume, raises testosterone into the normal adult range in most, and induces spermatogenesis in a majority, with pregnancies achieved (Delemarre-Van de Waal 1993 PMID 8330443; Buchter 1998 PMID 9758439; Christiansen 2002 PMID 12006717)
  • Can induce a pubertal growth spurt in hypogonadotropic adolescents during pulsatile therapy (Delemarre-Van de Waal 1993 PMID 8330443)
  • Continuous or supraphysiologic/non-pulsatile exposure suppresses rather than stimulates gonadotropins via receptor downregulation (mechanistic; same basis as GnRH-agonist castration)
  • No demonstrated effect on muscle mass, strength, fat loss, or performance; no human data support use as an hCG-equivalent or as an anabolic-steroid 'axis-maintenance' agent
Safety

Adverse effects by system

Cardiovascular

No characteristic direct cardiotoxicity reported for gonadorelin itself. The main acute cardiovascular risk is as part of a systemic anaphylactic/anaphylactoid reaction (hypotension, collapse) after IV administration (Akin 2015 PMID 26197466; Potashnik 1993 PMID 8437612). No controlled human cardiovascular safety data for chronic or recreational use.

Hepatic

No signal for direct hepatotoxicity; it is a rapidly-cleared endogenous peptide and moderate liver disease does not materially alter its clearance (Pimstone 1977 PMID 320223). No adequate human data on hepatic effects with recreational use.

Endocrine / HPTA

Endocrine effects are the primary pharmacology and are pattern-dependent: pulsatile dosing stimulates the LH/FSH-testosterone axis, whereas continuous or non-physiologic dosing downregulates pituitary GnRH receptors and suppresses gonadotropins. Improper (non-pulsatile) self-dosing can therefore blunt rather than support the axis (mechanistic; Lahlou 2005 PMID 16302716 for the agonist-desensitization principle).

Reproductive

Intended reproductive effects (increased testicular volume, testosterone, spermatogenesis, fertility) with proper pulsatile therapy (Buchter 1998 PMID 9758439; Christiansen 2002 PMID 12006717). Conversely, mistimed/continuous exposure can suppress the axis and impair gonadal function. No evidence it protects fertility during anabolic steroid use.

Neuropsychiatric

No well-characterized primary psychiatric adverse effects from gonadorelin in the primary literature. No adequate human data on mood/behavioral effects with recreational use; state explicitly that this is uncharacterized.

Renal

No direct nephrotoxicity described. Renal impairment prolongs GnRH half-life and reduces clearance, so renal disease is a pharmacokinetic (dosing/accumulation) consideration rather than a target of toxicity (Pimstone 1977 PMID 320223).

Hematologic

No characteristic hematologic toxicity reported and no adequate human hematologic safety data; state explicitly that hematologic effects are not established.

Dermatologic

Injection-site reactions (local irritation, redness) can occur with subcutaneous pulsatile pump delivery. Urticaria/skin manifestations can occur as part of a hypersensitivity/anaphylactic reaction (Akin 2015 PMID 26197466). No systematic dermatologic dataset.

Recovery

HPTA suppression & recovery

Suppression: Bidirectional and dosing-pattern dependent, not a reliable axis-recovery agent. Correctly-timed pulsatile delivery stimulates LH/FSH; continuous, high-dose, or mistimed exposure downregulates pituitary GnRH receptors and suppresses gonadotropins.

There is no adequate human evidence that intermittent subcutaneous gonadorelin restores or maintains the hypothalamic-pituitary-gonadal axis after anabolic steroid use, and it is not an established substitute for hCG. Because the wrong administration pattern can worsen suppression, self-managed 'restart' protocols are not supported. HPTA assessment and any recovery plan should be directed by an endocrinologist with serial bloodwork; do not self-treat suspected hypogonadism. This site does not endorse multi-drug or dual-SERM restart protocols.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and follow-up serum LH, FSH, and total testosterone (with SHBG/free testosterone as indicated)Estradiol where relevantSemen analysis if fertility/spermatogenesis is the therapeutic goalRenal function (eGFR/creatinine) — impaired renal function prolongs clearanceProlactin and broader pituitary panel when evaluating secondary hypogonadism, per endocrinologist

Cadence: Diagnostic use is a single supervised test. Therapeutic pulsatile use requires clinician-directed monitoring, typically every few weeks to months (hormones during titration; testicular volume and semen analysis over months, as spermatogenesis induction commonly takes 1-2 years). Any non-medical use should prompt formal endocrine evaluation rather than self-monitoring.

Warning signs — seek care
  • Signs of anaphylaxis after a dose: hives, flushing, itching, swelling of lips/face/throat, wheeze or difficulty breathing, dizziness, fainting, or seizure — call emergency services immediately
  • Persistent injection-site reaction, infection, or pump-site problems
  • Worsening rather than improving symptoms of low testosterone (fatigue, low libido, mood change), which may indicate axis suppression from improper dosing
  • Any new severe headache or visual change (prompt for pituitary evaluation)
Do not use if

Contraindications

  • Known hypersensitivity/prior anaphylactic or anaphylactoid reaction to gonadorelin or other GnRH analogues
  • Hormone-sensitive conditions where gonadotropin/sex-steroid stimulation is undesirable (e.g., known or suspected sex-hormone-dependent tumor) — requires physician judgment
  • Pregnancy/breastfeeding unless specifically directed by a clinician
  • Pituitary adenoma or other pituitary pathology without specialist evaluation (diagnostic and therapeutic interpretation is altered)
  • Administration outside a setting equipped to manage anaphylaxis (no resuscitation/epinephrine available) for IV use
  • Self-directed use as an anabolic-steroid adjunct or HPTA 'restart' agent — no human evidence of benefit and potential to worsen suppression
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Gonadorelin is not an hCG substitute and has no human evidence for maintaining testicular function or 'restarting' the axis during/after anabolic steroid use — do not rely on it for fertility protection or HPTA recovery.
  • Its effect depends on precise pulsatile timing; steady, high, or mistimed dosing can suppress rather than stimulate LH/FSH. This makes safe self-administration for axis support impractical.
  • Because anaphylaxis is documented (including a life-threatening case), any injection carries a real acute allergic risk; a first dose in particular should not be taken alone or without access to emergency care/epinephrine.
  • If you have symptoms of low testosterone or infertility, get a proper endocrine workup (LH, FSH, testosterone, prolactin, and clinical exam) rather than self-treating — the correct diagnosis (primary vs secondary hypogonadism) changes management entirely.
  • Stop immediately and seek emergency care for any allergic reaction (hives, swelling, breathing difficulty, faintness, seizure).
  • Renal impairment prolongs clearance — an additional reason dosing should be clinician-supervised.
  • Any therapeutic use should be under an endocrinologist, with baseline and follow-up bloodwork; do not self-design multi-drug or dual-SERM protocols.
Evidence

Citations (8)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Gonadorelin/GnRH has a very short plasma half-life (initial ~5.5-8 min in healthy subjects), is cleared rapidly, unchanged by moderate liver disease, and prolonged (~12-16.5 min) with reduced clearance in chronic renal failure; kidney is an important catabolic organ.

    CohortPMID 320223 ↗

  2. 02

    Long-term pulsatile intravenous GnRH in men with hypogonadotropic hypogonadism increased LH, FSH and testosterone, increased testicular volume, and induced spermatogenesis in the majority (31 of 38), and could induce a growth spurt in adolescents.

    CohortDOI 10.1111/j.1365-2265.1993.tb00342.x ↗

  3. 03

    Pulsatile GnRH (or hCG/hMG) is an effective treatment inducing spermatogenesis and paternity in men with secondary hypogonadism; sperm appeared in 54/57 courses and pregnancies in 26/36 across 42 cases.

    CohortDOI 10.1530/eje.0.1390298 ↗

  4. 04

    Subcutaneous pulsatile GnRH is a well-tolerated, effective therapy inducing spermatogenesis in most men with idiopathic hypogonadotropic hypogonadism (9/11), often requiring 1-2 years of treatment; cryptorchidism was a negative prognostic factor.

    CohortDOI 10.1159/000057944 ↗

  5. 05

    Pulsatile GnRH can induce testicular growth from infantile to adult size and normal spermatogenesis in hypogonadotropic hypogonadism (Kallmann syndrome).

    Case reportDOI 10.1055/s-2007-1013542 ↗

  6. 06

    Intravenous gonadorelin can cause severe, life-threatening anaphylaxis (pediatric case with loss of consciousness and seizures within 3 minutes, treated with epinephrine); administration should occur where systemic reactions can be managed.

    Case reportDOI 10.1515/jpem-2015-0183 ↗

  7. 07

    Anaphylactic reaction to gonadotropin-releasing hormone has been reported in an adult.

    Case reportDOI 10.1056/NEJM199303183281119 ↗

  8. 08

    Continuous/agonist GnRH exposure suppresses LH (via loss of pulsatility and receptor desensitization), the mechanistic basis for GnRH-analogue-induced gonadotropin suppression versus pulsatile stimulation.

    ReviewDOI 10.1016/s0003-4401(05)80013-0 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice